Statistics for Adjuvant Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors: Is This the Preferred Option?
Total visits
views | |
---|---|
Adjuvant Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors: Is This the Preferred Option? | 73 |
Total visits per month
views | |
---|---|
January 2024 | 0 |
February 2024 | 0 |
March 2024 | 0 |
April 2024 | 0 |
May 2024 | 0 |
June 2024 | 0 |
July 2024 | 0 |
File Visits
views | |
---|---|
Einhorn2020Adjuvant.pdf | 150 |
Top country views
views | |
---|---|
United States | 59 |
Canada | 3 |
China | 2 |
Japan | 1 |
Malaysia | 1 |
Sweden | 1 |
Top city views
views | |
---|---|
Wilmington | 36 |
Fairfield | 7 |
Houston | 6 |
Cambridge | 4 |
Toronto | 3 |
Beijing | 2 |
San Francisco | 2 |
Ann Arbor | 1 |
Seremban | 1 |
Stockholm | 1 |
Westbury | 1 |